Predict your next investment

Corporation
HEALTHCARE | Drug Manufacturing / OTC Medications
perrigo.com

See what CB Insights has to offer

Investments

2

Portfolio Exits

9

Partners & Customers

10

Service Providers

1

About Perrigo

Perrigo (NYSE: PRGO) (TASE: PRGO) is a global healthcare supplier that develops, manufactures, and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API), and consumer products.

Perrigo Headquarter Location

Treasury Building Lower Grand Canal St

Dublin,

Ireland

+353 (0)1 709 4000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Perrigo

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Perrigo in 2 Expert Collections, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

237 items

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Perrigo Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Perrigo Rank

Latest Perrigo News

Medisca Signs Deal as Exclusive Global Distributor outside the USA & Israel for the Padagis Line of ORA Products

Jan 12, 2022

Author of the article: Article content MONTREAL — On December 9, 2021, Medisca entered into an exclusive global manufacture, supply, license and distribution agreement with Padagis (formerly, the Rx Division of Perrigo) for their ORA Product Line consisting of the following Padagis products in finished form: ORA-Plus®, ORA-Sweet®, ORA-Sweet® SF, ORA-Blend®, and ORA-Blend® SF. With this, Medisca has exclusive distribution rights on all global markets except the United States and Israel, and non-exclusive distribution rights with contractual benefits in Australia. Advertisement Article content “This exclusive agreement reinforces Medisca’s commitment as a pioneer in personalized medicine around the world,” says Panagiota Danopoulos, Senior Vice President Global Strategy & Innovation, Medisca. “Partnering with Padagis is another important step in expanding our reach, as we continue to build the power of Medisca brands into a global trailblazer across the pharmaceutical compounding, scientific lab, cosmetic, and other healthcare industries.” We apologize, but this video has failed to load. Try refreshing your browser, or Medisca Signs Deal as Exclusive Global Distributor outside the USA & Israel for the Padagis Line of ORA Products Back to video Developed over 20 years ago by Paddock Laboratories, which was acquired by Perrigo in 2011, ORA products are manufactured by Padagis in Minnesota and are the longest-standing compounding oral vehicles on the market, with over 150 stability studies to support their use. In fact, this unmatched study portfolio is key to why many view ORA products as the go-to compounding oral vehicles across the globe. Outside of compounding, the ORA brand continues to make its mark, found in department stores as over the counter products and included as part of FDA-approved finished drugs. “Until now, the ORA Product Line has used multiple distributors worldwide,” says Colter VanStedum, Executive Vice President and Chief Growth Officer, Padagis. “Our decision to centralize distribution through Medisca was heavily influenced by their global distribution capabilities. The ORA products have vast potential in critical patient care – especially pediatric care – and should be widely available to pharmacists, physicians, and most importantly, patients – in all markets across the globe. Creating this partnership was a strategic move to maximize positive impact to patients around the world.” Danopoulos adds, “Medisca’s quality standard and international network are what allow an agreement like this to be signed. It is another key milestone in our commitment to growth and leadership, making a meaningful, sustainable difference in emerging markets.” With this agreement, Medisca will also be filing international trademark applications in certain countries in its name. About MEDISCA MEDISCA is a global leader in healthcare with well-established footings in pharmaceutical compounding and advancements in scientific labs, cosmetics, other healthcare industries. For 30+ years, MEDISCA has been serving pharmacies and allied healthcare institutions with cutting-edge offerings and passionate commitment, developing a worldwide network dedicated to personalized medicine. Through genuine relationships, worry-free experiences, convenient processes, and strategic global partnerships, MEDISCA provides top-quality and innovative products, industry-leading services, and world-class support systems. For more information about MEDISCA, please visit www.medisca.com , and follow us on Twitter at @ medisca . Advertisement

Perrigo Investments

2 Investments

Perrigo has made 2 investments. Their latest investment was in Kazmira as part of their Corporate Minority on June 6, 2020.

CBI Logo

Perrigo Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/17/2020

Corporate Minority

Kazmira

$50M

Yes

1

11/18/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/17/2020

11/18/2019

Round

Corporate Minority

Series B

Company

Kazmira

Subscribe to see more

Amount

$50M

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

1

10

Perrigo Portfolio Exits

9 Portfolio Exits

Perrigo has 9 portfolio exits. Their latest portfolio exit was Perrigo - Latin American Pharmaceutical Operations on May 18, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/18/2021

Divestiture

3

3/1/2021

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

6/19/2020

Acq - Fin

Subscribe to see more

$99M

Subscribe to see more

10

7/8/2019

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

5/8/2019

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/18/2021

3/1/2021

6/19/2020

7/8/2019

5/8/2019

Exit

Divestiture

Divestiture

Acq - Fin

Divestiture

Divestiture

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

Perrigo Acquisitions

20 Acquisitions

Perrigo acquired 20 companies. Their latest acquisition was HRA Pharma on September 08, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/8/2021

$99M

Acquired

4

8/11/2020

$99M

Acquired Unit

1

2/24/2020

$99M

Acquired Unit

1

5/9/2019

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

10

8/17/2016

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/8/2021

8/11/2020

2/24/2020

5/9/2019

8/17/2016

Investment Stage

Other Venture Capital

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$99M

Note

Acquired

Acquired Unit

Acquired Unit

Subscribe to see more

Subscribe to see more

Sources

4

1

1

10

10

Perrigo Partners & Customers

10 Partners and customers

Perrigo has 10 strategic partners and customers. Perrigo recently partnered with Probi on February 2, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

2/18/2021

Licensor

Probi

Sweden

Probi and Perrigo’s EU pact looks to develop probiotics for digestive and immune health

`` We believe our partnership with Michigan State University has the potential to yield customized transformative self-care solutions that can help our retail partners and our consumers make informed health and wellness decisions that are best for themselves and their families , '' commented Rich Sorota , Perrigo Executive Vice President and President , Consumer Self-Care Americas earlier this year .

1

1/11/2021

Partner

Michigan State University

United States

Perrigo And Michigan State University Announce Partnership To Advance Consumer Self-Care Innovation

Dr. Beauchamp previously spearheaded similar public-private partnerships focused on academic , technology and product innovation while serving in academic medicine leadership positions at Johns Hopkins University and the University of Washington .

1

1/11/2021

Partner

Michigan State University Foundation

United States

Perrigo And Michigan State University Announce Partnership To Advance Consumer Self-Care Innovation.

Dr. Beauchamp previously spearheaded similar public-private partnerships focused on academic , technology and product innovation while serving in academic medicine leadership positions at Johns Hopkins University and the University of Washington .

1

1/11/2021

Partner

Michigan State University

United States

Subscribe to see more

Subscribe to see more

10

11/9/2020

Partner

Michigan State University

United States

Subscribe to see more

Subscribe to see more

10

Date

2/18/2021

1/11/2021

1/11/2021

1/11/2021

11/9/2020

Type

Licensor

Partner

Partner

Partner

Partner

Business Partner

Probi

Michigan State University

Michigan State University Foundation

Michigan State University

Michigan State University

Country

Sweden

United States

United States

United States

United States

News Snippet

Probi and Perrigo’s EU pact looks to develop probiotics for digestive and immune health

`` We believe our partnership with Michigan State University has the potential to yield customized transformative self-care solutions that can help our retail partners and our consumers make informed health and wellness decisions that are best for themselves and their families , '' commented Rich Sorota , Perrigo Executive Vice President and President , Consumer Self-Care Americas earlier this year .

Perrigo And Michigan State University Announce Partnership To Advance Consumer Self-Care Innovation

Dr. Beauchamp previously spearheaded similar public-private partnerships focused on academic , technology and product innovation while serving in academic medicine leadership positions at Johns Hopkins University and the University of Washington .

Perrigo And Michigan State University Announce Partnership To Advance Consumer Self-Care Innovation.

Dr. Beauchamp previously spearheaded similar public-private partnerships focused on academic , technology and product innovation while serving in academic medicine leadership positions at Johns Hopkins University and the University of Washington .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Perrigo Service Providers

1 Service Provider

Perrigo has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired Unit

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acquired Unit

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Perrigo Team

14 Team Members

Perrigo has 14 team members, including current Chief Executive Officer, Michael Jandernoa.

Name

Work History

Title

Status

Michael Jandernoa

Chief Executive Officer

Current

Richard G. Hansen

President

Current

M. James Gunberg

Chief Financial Officer

Current

Ralph Klingenmeyer

Executive Vice President

Current

Paul E. Nicholson

Executive Vice President

Current

Name

Michael Jandernoa

Richard G. Hansen

M. James Gunberg

Ralph Klingenmeyer

Paul E. Nicholson

Work History

Title

Chief Executive Officer

President

Chief Financial Officer

Executive Vice President

Executive Vice President

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.